← FDA DRUG APPROVALS

FDA ANDA · ANDA076657

IFOSFAMIDE

Sponsor: MEITHEAL

APPLICATION
ANDA076657
TYPE
ANDA
ORIGINAL APPROVAL
2007-04-04
LATEST ACTION
2020-12-22
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

IFOSFAMIDEPrescription
IFOSFAMIDE 3GM/60ML (50MG/ML) · INJECTABLE · INJECTION
IFOSFAMIDEPrescription
IFOSFAMIDE 1GM/20ML (50MG/ML) · INJECTABLE · INJECTION

Approval history

2020-12-22Labeling · Supplement 29 · standardAP
2015-05-14Labeling · Supplement 25 · standard — Label ↗AP
2015-05-14Labeling · Supplement 17 — Label ↗AP
2015-05-14Labeling · Supplement 21 · standard — Label ↗AP
2014-06-13Labeling · Supplement 3AP
2007-04-04OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →